Cytometry Part B: Clinical Cytometry最新文献_第10页

IF 2.7 3区医学

Cytometry Part B: Clinical Cytometry Pub Date : 2025-11-04

引用次数: 0

A case of a mantle cell lymphoma with abundant and irregular cytoplasm: When you go with the flow. 细胞质丰富且不规则的套细胞淋巴瘤1例：当你随波逐流。

IF 2.7 3区医学

Cytometry Part B: Clinical Cytometry Pub Date : 2025-10-28 DOI: 10.1002/cyto.b.22261

Quentin Amiot, Anne-Margaux Legland Ép Dejean, Sarah Bugier, Pierre Arnautou, Jean-Valère Malfuson

引用次数: 0

IF 2.7 3区医学

Cytometry Part B: Clinical Cytometry Pub Date : 2025-10-27

引用次数: 0

A practical approach to panel design, validation, and interpretation for the evaluation of T-cell neoplasms by flow cytometry 一种实用的方法来面板设计，验证，并解释评价t细胞肿瘤流式细胞术。

IF 2.7 3区医学

Cytometry Part B: Clinical Cytometry Pub Date : 2025-10-22 DOI: 10.1002/cyto.b.22258

Jean Oak, Felipe Magalhaes Furtado, Katherine A. Devitt, Pedro Horna, Jonathan R. Fromm, Lianqun Qiu, Andrea Illingworth, Jolene Cardinali, Wolfgang Kern, Ahmad Al-Attar, Min Shi

{"title":"A practical approach to panel design, validation, and interpretation for the evaluation of T-cell neoplasms by flow cytometry","authors":"Jean Oak, Felipe Magalhaes Furtado, Katherine A. Devitt, Pedro Horna, Jonathan R. Fromm, Lianqun Qiu, Andrea Illingworth, Jolene Cardinali, Wolfgang Kern, Ahmad Al-Attar, Min Shi","doi":"10.1002/cyto.b.22258","DOIUrl":"10.1002/cyto.b.22258","url":null,"abstract":"The diagnosis of T-cell neoplasms remains one of the most challenging areas in hematopathology due to the immunophenotypic heterogeneity and subtle aberrancies often present in these entities. This “Best Practice” manuscript provides a practical framework for laboratories to design, validate, and interpret immunophenotyping studies of immature and mature T-cell neoplasms. We outline the utility of key antigens in the screening and classification of T-cell lymphomas/leukemia including TRBC1 and TRBC2. Analytical strategies using the “difference from normal” method and template-based gating are discussed, along with validation considerations aligned with CLSI H62 guidelines. By integrating these principles into laboratory workflows, this manuscript aims to standardize and improve the assessment of T-cell neoplasms across diverse clinical settings.","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":"108 6","pages":"430-447"},"PeriodicalIF":2.7,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cyto.b.22258","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145343874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of flow cytometric osmotic fragility test between kinetic and endpoint assay principle 流式细胞术渗透易碎性试验动力学原理与终点法原理的比较。

IF 2.7 3区医学

Cytometry Part B: Clinical Cytometry Pub Date : 2025-10-14 DOI: 10.1002/cyto.b.22254

Dong Il Won, Eui Yeol Jeong, Sang Mook Kim, Ye Jee Shim

{"title":"Comparison of flow cytometric osmotic fragility test between kinetic and endpoint assay principle","authors":"Dong Il Won, Eui Yeol Jeong, Sang Mook Kim, Ye Jee Shim","doi":"10.1002/cyto.b.22254","DOIUrl":"10.1002/cyto.b.22254","url":null,"abstract":"To screen hereditary spherocytosis (HS), we first introduced the novel flow cytometric osmotic fragility test (FC-OFT) based on the two-point kinetic assay principle (FC-OFTKinetic). With the introduction of FC systems with automatic tube loaders, we updated the FC-OFT protocol to follow the endpoint assay principle (FC-OFTEndpoint). This study aims to evaluate the updated FC-OFT protocol (FC-OFTEndpoint) and compare its assay performance with that of FC-OFTKinetic. We investigated factors influencing the FC-OFTEndpoint assay, optimized its protocol, and defined the cutoff index using 152 negative or artificially positive control samples. We then compared the assay performance with that of FC-OFTKinetic in 25 patients with anemia, including 14 with spherocytosis—8, 4, 1, and 1 with HS, autoimmune hemolytic anemia, burn injury, and liver cirrhosis, respectively. To optimize FC-OFTEndpoint, we adopted phosphate-buffered saline as the red cell suspension medium, 50% deionized water for hypotonic osmotic pressure in adults, and a 3-min standby time. This FC-OFTEndpoint was more accurate than FC-OFTKinetic in identifying spherocytosis in the 25 patients with anemia (p = 0.0313). FC-OFTEndpoint is a viable alternative to conventional OFT or FC-OFTKinetic for HS screening in clinical laboratories, as automatic FC enhances assay performance. These findings warrant validation in future multicenter studies with larger sample sizes.","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":"108 6","pages":"456-465"},"PeriodicalIF":2.7,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145285881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial Intelligence Issue Highlights 人工智能问题亮点

IF 2.7 3区医学

Cytometry Part B: Clinical Cytometry Pub Date : 2025-09-30 DOI: 10.1002/cyto.b.22257

Wolfgang Kern, Paul Wallace, Ryan Brinkman

引用次数: 0

AI in flow cytometry: Current applications and future directions 人工智能在流式细胞术中的应用现状及未来发展方向。

IF 2.7 3区医学

Cytometry Part B: Clinical Cytometry Pub Date : 2025-09-23 DOI: 10.1002/cyto.b.22255

Alice Yue, Ryan R. Brinkman, Veronica Nash, Fabian Junker, Goce Bogdanoski, Anagha Divekar, Aaron Tyznik, Josef Spidlen, Wolfgang Kern, Jordi Petriz, Kaska Wloka, Kamila Czechowska

引用次数: 0

IF 2.7 3区医学

Cytometry Part B: Clinical Cytometry Pub Date : 2025-09-17

引用次数: 0

Ad hoc antibody modification of a validated flow cytometric immunophenotyping panel—recommendations and safeguards for clinical laboratories 经过验证的流式细胞术免疫表型组的特设抗体修饰-临床实验室的建议和保障措施。

IF 2.7 3区医学

Cytometry Part B: Clinical Cytometry Pub Date : 2025-09-15 DOI: 10.1002/cyto.b.22253

Christopher J. Groves, Michael A. Linden, Ahmad Al-Attar, Michael J. Borowitz, Christoph Eberle, Marci O'Driscoll, Eleni Linskens, Jolene Cardinali, Thomas C. Beadnell, Wendy Shallenberger, Xiangyang Dong, Robert J. Durso, Sara A. Monaghan, Benjamin D. Hedley

{"title":"Ad hoc antibody modification of a validated flow cytometric immunophenotyping panel—recommendations and safeguards for clinical laboratories","authors":"Christopher J. Groves, Michael A. Linden, Ahmad Al-Attar, Michael J. Borowitz, Christoph Eberle, Marci O'Driscoll, Eleni Linskens, Jolene Cardinali, Thomas C. Beadnell, Wendy Shallenberger, Xiangyang Dong, Robert J. Durso, Sara A. Monaghan, Benjamin D. Hedley","doi":"10.1002/cyto.b.22253","DOIUrl":"10.1002/cyto.b.22253","url":null,"abstract":"Immunophenotyping by flow cytometry is a valuable test providing important information in a timely manner. In clinical laboratories, it is performed using validated antibody panels designed to ensure consistent and accurate results. However, unforeseen situations, such as unique or unusual immunophenotypes, or supply chain issues, may necessitate ad hoc modifications to these panels. This manuscript provides guidance for performing minor modifications, such as substituting or adding one or two antibodies, while maintaining the integrity of the assay. These modifications are intended for rare clinical situations and are not substitutes for the full validation protocols outlined in CLSI H62. An example of this would be a patient with a rare, but not uncommon, situation in which a B cell lymphoma lacks expression of CD19, CD20, and surface light chains, such that the lineage of the neoplastic cells cannot be determined without a straightforward addition or substitution of another marker into a laboratory's available panel. The recommendations and best practices herein aim to optimize patient care by allowing laboratories to adapt to unique clinical scenarios without compromising assay performance and are not a way to permanently modify the assay. Key considerations include assessing the impact on fluorescence compensation, antibody binding, assay sensitivity, and overall assay performance. The manuscript provides limitations for the extent of modifications, examples, and troubleshooting strategies to ensure reliable results when ad hoc changes are made. Proper documentation with review and approval by laboratory medical directors is recommended to mitigate risks associated with these modifications.","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":"110 1","pages":"11-21"},"PeriodicalIF":2.7,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stabilization of bronchoalveolar lavage cells for postponed flow cytometric analysis 用于延迟流式细胞分析的支气管肺泡灌洗细胞的稳定。

IF 2.7 3区医学

Cytometry Part B: Clinical Cytometry Pub Date : 2025-09-13 DOI: 10.1002/cyto.b.22250

Arianna Gatti, Laura Travaini, Francesca Borella, Annamaria Gorla, Gabriella Pagani, Irene Cuppari, Bruno Brando

引用次数: 0